Literature DB >> 11285571

Differential IgM response to conformational and linear epitopes of parvovirus B19 VP1 and VP2 structural proteins.

E Manaresi1, E Zuffi, G Gallinella, G Gentilomi, M Zerbini, M Musiani.   

Abstract

The IgM immune response against conformational and linear epitopes of B19 structural proteins VP1 and VP2 was examined in serum samples with a suspect B19 infection to determine the most suitable antigen for use in IgM detection and also to evaluate a possible relationship between the course of B19 infection and the presence of epitope type-specific IgM. The detection of IgM against conformational epitopes was performed by ELISA using undenatured VP1 and VP2 antigens whereas the detection of IgM against linear epitopes was performed by Western blot assays using denatured VP1 and VP2. IgM immune response against VP1 conformational epitopes appeared dominant, being detected in all serum samples positive for specific IgM, whereas IgM against VP2 linear antigen were found less frequently, being identified in less than half of the B19 IgM positive sera. In the examination of the course of infection, IgM against VP1 conformational epitopes appeared in the active phase of B19 infection at the same time and with the same frequency as IgM anti VP2 conformational epitopes and anti linear VP1 epitopes. IgM against VP1 conformational epitopes were seen to be long-lasting because in the recent phase of infection they were still present when other specific IgM were absent. During the active phase of B19 infection, IgM against VP2 linear epitopes were less frequently found than other specific IgM and in the recent phase they underwent a rapid temporal diminution. The data demonstrate that a sensitive B19 IgM test needs to be performed in diagnostic laboratories by ELISA using conformational B19 antigens; Western blot assays can be used only as confirmatory tests using VP1 linear antigens. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11285571     DOI: 10.1002/jmv.1019

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  Comparison of three commercially available serologic assays used to detect human parvovirus B19-specific immunoglobulin M (IgM) and IgG antibodies in sera of pregnant women.

Authors:  Allyson R Butchko; Jeanne A Jordan
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

2.  Identification and characterization of persistent human erythrovirus infection in blood donor samples.

Authors:  Daniel Candotti; Nermin Etiz; Armen Parsyan; Jean-Pierre Allain
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

3.  Reactivity of genotype-specific recombinant proteins of human erythrovirus B19 with plasmas from areas where genotype 1 or 3 is endemic.

Authors:  Armen Parsyan; Shane Kerr; Shirley Owusu-Ofori; Gordon Elliott; Jean-Pierre Allain
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

4.  Human IgM monoclonal antibodies block HIV-transmission to immune cells in cervico-vaginal tissues and across polarized epithelial cells in vitro.

Authors:  Claudia Devito; Rada Ellegård; Tina Falkeborn; Lennart Svensson; Mats Ohlin; Marie Larsson; Kristina Broliden; Jorma Hinkula
Journal:  Sci Rep       Date:  2018-07-05       Impact factor: 4.379

Review 5.  Advances in the Development of Antiviral Strategies against Parvovirus B19.

Authors:  Elisabetta Manaresi; Giorgio Gallinella
Journal:  Viruses       Date:  2019-07-18       Impact factor: 5.048

6.  Serodiagnosis of human bocavirus infection.

Authors:  Kalle Kantola; Lea Hedman; Tobias Allander; Tuomas Jartti; Pasi Lehtinen; Olli Ruuskanen; Klaus Hedman; Maria Söderlund-Venermo
Journal:  Clin Infect Dis       Date:  2008-02-15       Impact factor: 9.079

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.